Ultimately, this leads to the emergence of aggressive breast cancer subpopulations characterized by either high levels of KDM7A-DT in luminal A and basal-like/triple-negative forms or low levels in luminal B and HER2-positive types, highlighting the molecule’s critical role across different cancer subtypes. This evidence concerns the gene ERBB2 and breast carcinoma.